Literature DB >> 21250778

Soluble CD36- a marker of the (pathophysiological) role of CD36 in the metabolic syndrome?

Debby P Y Koonen1, Majken K Jensen, Aase Handberg.   

Abstract

CD36 is a class B scavenger receptor observed in many cell types and tissues throughout the body. Recent literature has implicated CD36 in the pathogenesis of metabolic dysregulation such as found in obesity, insulin resistance, and atherosclerosis. Genetic variation at the CD36 loci have been associated with obesity and lipid components of the metabolic syndrome, with risk of heart disease and type 2 diabetes. Recently, non-cell bound CD36 was identified in human plasma and was termed soluble CD36 (sCD36). In this review we will describe the functions of CD36 in tissues and address the role of sCD36 in the context of the metabolic syndrome. We will also highlight recent findings from human genetic studies looking at the CD36 locus in relation to metabolic profile in the general population. Finally, we present a model in which insulin resistance, oxLDL, low-grade inflammation and liver steatosis may contribute to elevated levels of sCD36.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21250778     DOI: 10.3109/13813455.2010.543136

Source DB:  PubMed          Journal:  Arch Physiol Biochem        ISSN: 1381-3455            Impact factor:   4.076


  14 in total

1.  Reduced sCD36 following weight loss corresponds to improved insulin sensitivity, dyslipidemia and liver fat in obese children.

Authors:  L Knøsgaard; K Kazankov; N H Birkebæk; P Holland-Fischer; A Lange; J Solvig; A Hørlyck; K Kristensen; S Rittig; H Vilstrup; H Grønbæk; A Handberg
Journal:  Eur J Clin Nutr       Date:  2016-06-08       Impact factor: 4.016

2.  Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls.

Authors:  S Heebøll; M K Poulsen; M J Ornstrup; T N Kjær; S B Pedersen; S Nielsen; H Grønbæk; A Handberg
Journal:  Int J Obes (Lond)       Date:  2016-12-05       Impact factor: 5.095

3.  The effect of low-dose marine n-3 fatty acids on plasma levels of sCD36 in overweight subjects: a randomized, double-blind, placebo-controlled trial.

Authors:  Stine Krogh Venø; Michael René Skjelbo Nielsen; Søren Lundbye-Christensen; Erik Berg Schmidt; Aase Handberg
Journal:  Mar Drugs       Date:  2013-08-30       Impact factor: 5.118

4.  Circulating sCD36 is associated with unhealthy fat distribution and elevated circulating triglycerides in morbidly obese individuals.

Authors:  L Knøsgaard; S B Thomsen; M Støckel; H Vestergaard; A Handberg
Journal:  Nutr Diabetes       Date:  2014-04-07       Impact factor: 5.097

5.  Circulating CD36 and oxLDL levels are associated with cardiovascular risk factors in young subjects.

Authors:  Luz E Ramos-Arellano; José F Muñoz-Valle; Ulises De la Cruz-Mosso; Aralia B Salgado-Bernabé; Natividad Castro-Alarcón; Isela Parra-Rojas
Journal:  BMC Cardiovasc Disord       Date:  2014-04-28       Impact factor: 2.298

Review 6.  The Role of CD36 in Type 2 Diabetes Mellitus: β-Cell Dysfunction and Beyond.

Authors:  Jun Sung Moon; Udayakumar Karunakaran; Elumalai Suma; Seung Min Chung; Kyu Chang Won
Journal:  Diabetes Metab J       Date:  2020-04       Impact factor: 5.376

7.  Plasma CD36 and Incident Diabetes: A Case-Cohort Study in Danish Men and Women.

Authors:  Yeli Wang; Jingwen Zhu; Sarah Aroner; Kim Overvad; Tianxi Cai; Ming Yang; Anne Tjønneland; Aase Handberg; Majken K Jensen
Journal:  Diabetes Metab J       Date:  2019-10-18       Impact factor: 5.376

8.  Plasma sCD36 as non-circadian marker of chronic circadian disturbance in shift workers.

Authors:  Daniella van de Langenberg; Jelle J Vlaanderen; Martijn E T Dolle; Aase Handberg; Roel C H Vermeulen; Linda W M van Kerkhof
Journal:  PLoS One       Date:  2019-10-24       Impact factor: 3.240

9.  Lack of pronounced changes in the expression of fatty acid handling proteins in adipose tissue and plasma of morbidly obese humans.

Authors:  Ewa Anna Grzegorczyk; Ewa Harasim-Symbor; Bartlomiej Lukaszuk; Dorota Harasiuk; Barbara Choromanska; Piotr Mysliwiec; Malgorzata Zendzian-Piotrowska; Adrian Chabowski
Journal:  Nutr Diabetes       Date:  2018-01-15       Impact factor: 5.097

Review 10.  Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?

Authors:  Patricia Rada; Águeda González-Rodríguez; Carmelo García-Monzón; Ángela M Valverde
Journal:  Cell Death Dis       Date:  2020-09-25       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.